• Search
  • Helpdesk
  • Sales contact
Get your demo

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

CSR
Last updated: May 6, 2025

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Download the infographic
Ask for more information
Follow us on social media
Subscribe to our newsletter
You may also like

Kayentis accelerates US growth with 40% surge in bookings over...

Empowering patients through education – A structured approach to clinical...

Kayentis introduces its Patient Education Video Library to strengthen clinical...

Expanding investor confidence: The strategic value of Patient Reported Outcomes...

Leveraging the potential of Patient Reported Outcome (PRO) data to...

Gastrointestinal Tract Diseases Research: Moving Towards Patient-Centered Clinical Trials

About the author
Picture of Marc Chaperon

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.
Meet us at the following events

SCOPE Europe 2025

OCT 14-15 2025 • Barcelona, Spain
SCOPE Europe | Summit for Clinical Operations Executives | October 14-15, 2025 |Barcelona, Spain

Rethinking Phase 1 Oncology Trials with Electronic Patient-Reported Outcomes

November 4 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET
,
The primary aim of Phase 1 oncology clinical trials is to determine the safety of a new treatment, and to...